COVID-19 Vaccination Policy

Scripps Research is committed to protecting the health and wellness of its community of researchers, students, postdoctoral scholars, interns, and the many staff who support research and education programs on both its La Jolla, California and Jupiter, Florida campuses.

The ongoing COVID-19 pandemic and the evolving nature of the threat posed by new variants of the SARS CoV-2 virus remains a significant risk to the safety of our Scripps Research community. COVID-19 vaccines have been proven safe and effective in reducing infection and serious disease. The overwhelming majority of new COVID-19 cases, hospitalizations and deaths now occur in unvaccinated persons, who are more likely to get infected and spread the virus.

In view of these facts and the dynamic nature of this pandemic, Scripps Research has implemented a mandatory vaccination policy for all personnel on both of its campuses.

Policy

To help maintain the health and safety of the Scripps Research community, effective September 15, 2021, all personnel must be fully vaccinated against COVID-19 and certify their COVID-19 vaccination status through the institute’s online platform. Non-compliance with this Policy threatens the health of others in the Scripps Research community and jeopardizes the important research conducted at Scripps Research. Refusal to comply with this Policy will not be tolerated and will lead to disciplinary action ranging from restricted access to campus facilities up to termination of employment/dismissal from the Graduate Program.

Scope

This Policy applies to all members of the Scripps Research community accessing Scripps Research facilities, including but not limited to employees, students, postdocs, trainees, temporary workers, collaborators, vendors, contractors, and visitors.

Accommodations

Accommodations based on medical reasons or sincerely held religious beliefs will be made in accordance with applicable law, on a case-by-case basis. Such accommodations will include required mitigation measures to reduce or eliminate the risk of exposing other employees in the workplace to SARS-CoV-2, including, but not limited to: weekly screening and/or diagnostic testing, limited in person meetings, stringent face covering requirements, and social distancing requirements.

Fully Vaccinated

Personnel are considered fully vaccinated two weeks after receiving: (a) the second dose in a two-dose COVID-19 vaccine series or a singledose COVID-19 vaccine. Vaccines must be FDA approved, have an emergency use authorization from the FDA, or, for persons vaccinated outside the United States, be listed for emergency use by the World Health Organization (“WHO”). All COVID-19 vaccines that are currently authorized for emergency use can be found at the following links:

Learn More

Researchers and graduate students at Scripps Research have been at the forefront of studying SARS CoV-2 in search of treatments, and in communicating the complex topics surrounding this virus (and the disease it causes) to general audiences in clear, understandable terms. The videos below offer more insight into COVID-19, via short, succinct animations on specific topics, and in more detailed explorations of COVID-19 research led by Scripps Research scientists.

How Vaccines Work Against COVID-19

How New Variants Affect the Coronavirus

Extensive Study Identifies Over a Dozen Existing Drugs as Potential COVID-19 Therapies

How Spike Protein Discoveries Drove Coronavirus Vaccine Design